CBIONasdaqPharmaceutical PreparationsFiscal year ends December 31

CRESCENT BIOPHARMA, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026

$12.36+0.52 (+4.39%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

CRESCENT BIOPHARMA, INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31
Revenue	11	–	0.01	0.08	1.16	10	–	–	–	0.02	20	15	3.99	15
Research & Development	138	14	20	28	47	45	47	40	24	23	25	20	12	9.44
Selling, General & Admin	–	–	–	–	–	–	–	–	–	–	–	6.60	2.90	2.18
General & Administrative	25	18	19	19	17	17	14	11	9.83	8.65	7.81	6.60	2.90	–
Operating Expenses	163	40	39	47	65	62	61	52	34	32	33	26	–	–
Operating Income	-153	-40	-39	-47	-63	-52	-61	-52	-34	-32	-13	-11	-11	3.64
Interest Expense	2.19	–	–	–	–	–	–	–	–	–	–	–	–	–
Other Non-Operating Income	–	2.16	2.38	–	–	–	–	–	0.65	0.10	0.02	0.02	0.00	0.02
Merger & Restructuring Charges	–	7.00	–	–	–	–	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	–	1.22	-0.01	0.00	0.00	–	–	0.00	–	–	-0.01	0.00	–	–
Pretax Income	-152	–	–	–	–	–	–	–	–	–	–	–	–	–
Income Tax Expense	2.00	–	–	–	–	–	–	–	–	–	–	–	–	–
Net Income incl. Noncontrolling Interests	–	-38	-37	-47	-63	-51	-58	-48	-33	-32	–	–	–	–
Net Income	-154	-38	-37	-47	-63	-51	-58	-48	-33	-32	-13	-11	-11	3.66
Net Income to Common	-133	–	–	–	–	–	–	–	–	–	–	–	–	–
EPS (Basic)(per share)	–	-0.59	-0.58	-0.89	-1.23	-1.12	-1.34	-1.18	-1.13	-1.50	-0.67	-0.60	-8.87	3.93
EPS (Diluted)(per share)	–	-0.59	-0.58	-0.89	-1.23	-1.12	-1.34	-1.18	-1.13	-1.50	-0.67	-0.60	-8.87	0.33
Shares Outstanding (Basic, Weighted)(shares)	–	64	63	53	51	46	43	41	29	21	19	18	1.20	0.93
Shares Outstanding (Diluted, Weighted)(shares)	–	64	63	53	51	46	43	41	29	21	19	18	1.20	11

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: -1553.6%
Net margin: -885.5%
Return on equity, FY2025: -164.2%

Financial strength

Current ratio: 9.66
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 925.7%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –